SNY Jan 2024 50.000 call
| Previous close | 3.25 |
| Open | 6.94 |
| Bid | 5.10 |
| Ask | 7.00 |
| Strike | 50.00 |
| Expiry date | 2024-01-19 |
| Day's range | 6.94 - 6.94 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.16k |
- Motley Fool
Is Sanofi Stock a Buy Now?
French pharmaceutical giant Sanofi (NASDAQ: SNY) has long been a leader in the market for insulin. First, Sanofi was forced to decrease the price of its most prescribed insulin product after its only two real competitors in this area did something similar. Second, Sanofi announced the acquisition of Provention Bio, a biotech focusing on developing medicines to delay or prevent the onset of autoimmune diseases, such as Type 1a diabetes.
- Zacks
Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
- Zacks
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
